Guardant Health Inc (NASDAQ:GH) Receives $113.50 Average PT from Brokerages

Shares of Guardant Health Inc (NASDAQ:GH) have received an average recommendation of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $113.50.

Several analysts have recently commented on GH shares. Canaccord Genuity restated a “buy” rating and set a $125.00 price objective (up from $96.00) on shares of Guardant Health in a research report on Wednesday, August 7th. JPMorgan Chase & Co. lifted their price target on shares of Guardant Health from $90.00 to $135.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Cowen set a $110.00 price target on shares of Guardant Health and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, Zacks Investment Research downgraded shares of Guardant Health from a “strong-buy” rating to a “hold” rating in a report on Saturday, August 10th.

In other Guardant Health news, Chairman Amirali Talasaz sold 100,000 shares of Guardant Health stock in a transaction on Friday, August 16th. The shares were sold at an average price of $100.17, for a total value of $10,017,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ian T. Clark sold 2,690 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $85.70, for a total transaction of $230,533.00. Following the completion of the sale, the director now owns 3,992 shares in the company, valued at $342,114.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,004,867 shares of company stock worth $100,483,206. 13.00% of the stock is currently owned by insiders.



Several institutional investors have recently bought and sold shares of GH. Bank of America Corp DE bought a new stake in shares of Guardant Health in the 4th quarter worth about $250,000. Deutsche Bank AG bought a new stake in shares of Guardant Health in the 4th quarter worth about $713,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Guardant Health during the 1st quarter worth about $210,000. SG Americas Securities LLC purchased a new position in shares of Guardant Health during the 1st quarter worth about $108,000. Finally, Rhumbline Advisers boosted its stake in shares of Guardant Health by 1.8% during the 1st quarter. Rhumbline Advisers now owns 20,247 shares of the company’s stock worth $1,553,000 after purchasing an additional 367 shares during the period. Hedge funds and other institutional investors own 81.40% of the company’s stock.

Shares of GH stock traded up $0.55 on Monday, hitting $77.05. 968,957 shares of the stock traded hands, compared to its average volume of 1,025,245. The firm has a market cap of $7.07 billion and a price-to-earnings ratio of -27.52. Guardant Health has a 52 week low of $27.04 and a 52 week high of $112.21. The firm has a 50 day simple moving average of $93.52 and a two-hundred day simple moving average of $81.97.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.21. The firm had revenue of $53.98 million for the quarter, compared to the consensus estimate of $35.97 million. Guardant Health had a negative net margin of 60.08% and a negative return on equity of 22.93%. The company’s revenue was up 178.5% on a year-over-year basis. During the same period last year, the firm earned ($1.75) EPS. Analysts forecast that Guardant Health will post -1.27 earnings per share for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.

Featured Article: The Role of a Fiduciary and Individual Investors

Analyst Recommendations for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.